Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-03-29
2011-03-29
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S170000
Reexamination Certificate
active
07915244
ABSTRACT:
Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
REFERENCES:
patent: 4404366 (1983-09-01), Boguslaski et al.
patent: 5120723 (1992-06-01), Gee et al.
patent: 5206415 (1993-04-01), Covey et al.
patent: 5212167 (1993-05-01), Farb
patent: 5232917 (1993-08-01), Bolger et al.
patent: 5292906 (1994-03-01), Covey et al.
patent: 5344826 (1994-09-01), Covey et al.
patent: 5366968 (1994-11-01), Farb
patent: 5550120 (1996-08-01), Jackson
patent: RE35517 (1997-05-01), Gee et al.
patent: 5633011 (1997-05-01), Dong et al.
patent: 5728688 (1998-03-01), Labrie
patent: 5763431 (1998-06-01), Jackson
patent: 5763492 (1998-06-01), Johnson et al.
patent: 5767117 (1998-06-01), Moskowitz
patent: 5780460 (1998-07-01), Labrie
patent: 5798347 (1998-08-01), Labrie
patent: 5807849 (1998-09-01), Labrie
patent: 5824671 (1998-10-01), Labrie
patent: 5837544 (1998-11-01), Capon et al.
patent: 5837700 (1998-11-01), Labrie
patent: 5843932 (1998-12-01), Labrie
patent: 5872114 (1999-02-01), Labrie
patent: 5888996 (1999-03-01), Farb
patent: 5922700 (1999-07-01), Labrie
patent: 5925630 (1999-07-01), Upasani et al.
patent: 5929061 (1999-07-01), Moskowitz
patent: 5939545 (1999-08-01), Upasani et al.
patent: 5942241 (1999-08-01), Chasin et al.
patent: 5955455 (1999-09-01), Labrie
patent: 6114388 (2000-09-01), Geffard
patent: 6245757 (2001-06-01), Chopp et al.
patent: 7473687 (2009-01-01), Hoffman et al.
patent: 2001/0001280 (2001-05-01), Dong et al.
patent: 2009/0221544 (2009-09-01), Stein et al.
patent: 2009/0325920 (2009-12-01), Hoffman et al.
patent: WO 89/02272 (1989-03-01), None
patent: WO 94/23708 (1994-10-01), None
patent: WO97/43989 (1997-11-01), None
patent: WO 98/50042 (1998-11-01), None
patent: WO 02/30409 (2002-04-01), None
Allolio, B., et al., “High-Dose Progesterone Infusion in Healthy Males: Evidence Against Antiglucocorticord Activity of Progesterone,”European J. Endocrin., 1995, pp. 696-700, vol. 133.
Bender, A.S. and M.D., Norenberg, “Effect of Benzodiazepines and Neurosteroids on Ammonia-Induced Swelling in Cultured Astrocytes,”J. Neurosci. Res., 1998, pp. 673-680, vol. 54.
Canonaco, M., et al., “Steroid Hormones and Receptors of the GABAaSupramolecular Complex,”Neuroendocrinology, 1993, pp. 974-984, vol. 57.
Celotti, F., et al., “The 5α-Reductase in the Brain: Molecular Aspects and Relation to Brain Function,”Frontiers in Neuroendocrinology, 1992, pp. 163-215, vol. 13(2).
Cervantes, M., et al., “Brain Injury Following Cardiorespiratory Arrest in Cats, Effects of Alphaxolone Alphadolone,”Bol. Estud. Med. Biol., 1989, pp. 17-27, vol. 37.
Chen, J., et al., “Neuroprotective Effects of Progesterone After Transient Middle Cerebral Artery Occlusion,”J.Neurol. Sci., 1999, pp. 24-30, vol. 171.
Cutler, S., et al., “Tapered Progesterone Withdrawal Enhances Behavioral and Molecular Recovery After Traumatic Brain Injury,”Experimental Neurology, 2005, pp. 423-429, vol. 195, Elsevier, Inc.
Cutler, S., et al., “Tapered Progesterone Withdrawal Promotes Long-Term Recovery Following Brain Trauma,”Experimental Neurology, 2006, pp. 378-385, vol. 200, Elsevier, Inc.
Djebaili, M., et al., “Allopregnanolone and Progesterone Decrease Cell Death and Cognitive Deficits After a Contusion of the Rat Pre-Frontal Cortex,”Neuroscience, 2004, pp. 349-359, vol. 123.
Djebaili, M., et al., “The Neurosteroids Progesterone and Allopregnanolone Reduce Cell Death, Gliosis, and Functional Deficits After Traumatic Brain Injury in Rats,”J. Neurotrauma, 2005 pp. 106-118, vol. 2.
Fleming, G., et al., “Megestrol Acetate Reverses Multidrug Resistance and Interacts with P-glycoprotein,”Cancer Chemother Pharmacol, 1992, pp. 445-449, vol. 29.
Gee, K., “Steroid Modulation of the GABA/Benzodiazepine Receptor-Linked Chloride Ionophore,”Molecular Neurobiology, 1998, pp. 291-317, vol. 2.
Ghezzi, P., et al., “Neurosteroid Levels are Increased in vivo after LPS Treatment and Negatively Regulate LPS-induced TNF Production,”European Cytokine Network, 2000, pp. 464-449, vol. 11(3).
Goss, C., et al., “Behavioral Effects and Anatomic Correlates After Brain Injury: A Progesterone Dose—Response Study,”Pharmacology, Biochemistry and Behavior, 2003, pp. 231-242, vol. 76, Elsevier, Inc.
Grossman, K., et al., “Effects of Progesterone on the Inflammatory Response to Brain Injury in the Rat,”Brain Res., 2004, pp. 29-39, vol. 1008.
Hawkinson, J., et al., “Substituted 3β-Phenylethynyl Derivatives of 3α-Hydroxy-5α-pregnan-20-one: Remarkably Potent Neuroactive Steroid Modulators of γ-Aminobutyric AcidAReceptors,”J. Pharmacology and Experimental Therapeutics, 1998, pp. 198-207, vol. 287(1).
He, J., et al., “Alopregnanolone Facilitates Spatial Learning After Traumatic Brain Injury,”Soc. Neurosci. Abstr., 2000, 26: 2296 (862.4).
Hoffman, S., et al., “Allopregnanolone Reduces Edema After Controlled Cortical Impact Injury in Rats,”Soc. Neurosci. Abstr., 2000, 26: 967 (E30).
Jiang, N., et al., “Progesterone is Neuroprotective after Transient Middle Cerebral Artery Occlusion in Male Rats,”Brain Research, 1996, pp. 101-107, vol. 735.
Lambert, J., et al., “Neurosteroid Modulation of Native and Recombinant GABAAReceptors,”Cellular and Molecular Neurobiology, 1996, pp. 155-174, vol. 16(2).
Limmroth, V., et al., “GABAA-Receptor-Mediated Effects of Progesterone, Its Ring-A-Reduced Metabolites and Synthetic Neuroactive Steroids on Neurogenic Oedema in the Rat Meninges,”British Journal of Pharmacology, 1996, pp. 99-104, vol. 117.
Maurice, T., et al., “Neuroactive Neurosteroids as Endongenous Effectors for the Sigma1(σ1) Receptor Pharmacological Evidence and Therapeutic Opportunities,”Jpn. J. Pharmacol., 1999, pp. 125-155, vol. 81.
Melcangi, R., et al., “Steroid Metabolism and Effects in Central and Peripheral Glial Cells,”J. Neurobiol., 1999, pp. 471-483, vol. 40.
Michaels, E., “Cognitive Rehabilitation Advanced by Multifaceted Research, Conference Told,”Can. Med. Assoc. J.., 1995, pp. 465-467, vol. 153.
Monaghan, E., et al., “Initial Human Experience with Ganaxolone, A Neuroactive Steroid with Antiepileptic Activity,”Epilepsia, 1997, pp. 1026-1031, vol. 38(9).
Roof, R.L. and M.E. Fritts, “Progesterone Metabolites May Mediate Its Neuroprotective Effects After Traumatic Brain Injury,”J. Neurotrauma, 1997, pp. 760 vol. 14(12).
Roof, R.L. and E.D. Hall, “Gender Differences in Acute CNS Trauma and Stroke: Neuro-protective Effects of Estrogen and Progesterone,”J. Neurotrauma, 2000 pp. 367-388, vol. 17.
Roof, et al., “Progesterone Treatment Attenuates Brain Edema Following Contusion Injury in Male and Female Rats,”Restorative Neurology and Neuroscience, 1992, pp. 425-427, vol. 4.
Roof, R., et al., “Progesterone Facilitates Cognitive Recovery and Reduces Secondary Neuronal Loss Caused by Cortical Contusion Injury in Male Rats,”Experimental Neurology, 1994, pp. 64-69, vol. 129.
Roof, R., et al., “Progesterone Protects Against Lipid Peroxidation Following Traumatic Brain Injury in Rats,”Molecular and Chemical Neuropathology, 1997, pp. 1-11, vol. 31.
Roof, R.L., et al., “Progesterone Rapidly
Hoffman Stuart W.
Kellermann Arthur L.
Lowery-North Douglas W.
Stein Donald G.
Wright David W.
Emory University
Foley & Lardner LLP
Hui San-ming
LandOfFree
Methods for the treatment of a traumatic central nervous injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of a traumatic central nervous injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of a traumatic central nervous injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2631814